Comparative Molecular Docking and ADMET Analysis of Bioactive Compounds from Curcuma xanthorrhiza and Momordica charantia as Potential DPP-4 Inhibitors
Authors
Abstract
Background: Type 2 Diabetes Mellitus (T2DM) is characterized by impaired insulin secretion and insulin resistance. Dipeptidyl Peptidase-4 (DPP-4) regulates glucose homeostasis by degrading incretin hormones such as GLP-1, making it a key therapeutic target. Natural bioactive compounds from Curcuma xanthorrhiza and Momordica charantia have demonstrated antidiabetic potential, but comparative evaluation of their activity as DPP-4 inhibitors remains limited. Methods: Molecular docking was performed using CB-Dock2 integrated with AutoDock Vina against DPP-4 (PDB ID: 4A5S). Curcumin and xanthorrhizol from C. xanthorrhiza, and momordicin I and kuguacin J from M. charantia were evaluated. Sitagliptin was used as a positive control. Binding affinities and interactions with catalytic residues were analyzed. Pharmacokinetic and toxicity profiles were predicted using SwissADME and pkCSM. Results: All compounds demonstrated favorable binding affinities (< –7.0 kcal/mol). Kuguacin J exhibited the strongest binding (–8.7 kcal/mol), slightly exceeding sitagliptin (–8.5 kcal/mol), followed by momordicin I (–8.3 kcal/mol), curcumin (–8.2 kcal/mol), and xanthorrhizol (–7.3 kcal/mol). Key interactions involved Glu205, Glu206, Ser630, Tyr547, and Tyr662, indicating active-site occupation. ADMET analysis showed compliance with Lipinski’s rule of five and high gastrointestinal absorption for all compounds. Kuguacin J demonstrated the most favorable safety profile with no predicted Ames toxicity or hepatotoxicity. Conclusion: Kuguacin J emerges as the most promising natural DPP-4 inhibitor candidate based on combined docking and ADMET evaluation. Further experimental validation is required to confirm its therapeutic potential in T2DM management.
Keywords
References
- Ahmad, N., Hasan, N., Ahmad, Z., Zishan, M., & Zohrameena, S. (2016). Momordica Charantia: For Traditional Uses And Pharmacological Actions. Journal of Drug Delivery and Therapeutics, 6(2). https://doi.org/10.22270/jddt.v6i2.1202
- Amin, S., Heryanto, P., Athaya, R., & Fitri, N. A. (2024). Perkembangan Terkini dalam Desain Obat Berbasis Kimia Medisinal. Jurnal Ilmu Medis Indonesia, 4(1), 93. https://doi.org/10.35912/jimi.v4i1.4558
- Amin, S., Heryanto, P., Athaya, R., & Fitri, N. A. (2025). Perkembangan Terkini dalam Desain Obat Berbasis Kimia Medisinal. Jurnal Ilmu Medis Indonesia, 5(1), 41. https://doi.org/10.35912/jimi.v5i1.4558
Show 28 more references
- Ancuceanu, R., Lascu, B. E., Drăgănescu, D., & Dinu, M. (2025). [Review of In Silico ADME Methods Used in the Evaluation of Natural Products]. Pharmaceutics, 17(8), 1002. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/pharmaceutics17081002
- Arba, M., Ruslin, R., Akib, N. I., Yamin, Y., Sabarudin, S., Jessi, J., … Tjahjono, D. H. (2018). Molecular modeling of 4-fluoropyrrolidine-2-carbonitrile and octahydrocyclopenta[b]pyrrole-2-carbonitrile as a dipeptidyl peptidase IV (DPP4) inhibitor. Journal of Applied Pharmaceutical Science, 8(10), 1. https://doi.org/10.7324/japs.2018.81001
- Baziar, L., Emami, L., Rezaei, Z., Solhjoo, A., Sakhteman, A., & Khabnadideh, S. (2024). Design, synthesis, biological evaluation and computational studies of 4-Aminopiperidine-3, 4-dihyroquinazoline-2-uracil derivatives as promising antidiabetic agents. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-77481-9
- Castro‐Juárez, C. J., Ramírez‐García, S. A., Villa‐Ruano, N., & García‐Cruz, D. (2018). Genetic epidemiology on casual theories and pathogenesis of type 2 diabetes mellitus. Gaceta Médica de México, 153(7). https://doi.org/10.24875/gmm.m18000086
- Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. https://doi.org/10.1038/srep42717
- Deacon, C. F. (2019). [Review of Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes]. Frontiers in Endocrinology, 10, 80. Frontiers Media. https://doi.org/10.3389/fendo.2019.00080
- Drucker D. J. (2007). Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes care, 30(6), 1335–1343. https://doi.org/10.2337/dc07-0228
- Fakih, T. M., & Dewi, M. L. (2021). Interaksi Molekuler Inhibitor Dipeptidyl Peptidase-Iv (Dpp-Iv) Dari Protein Susu Kambing Secara In Silico Sebagai Kandidat Antidiabetes. Media Farmasi Jurnal Ilmu Farmasi, 17(1), 13. https://doi.org/10.12928/mf.v17i1.16249
- Farkhani, A., Sauriasari, R., & Yanuar, A. (2020). In Silico Approach For Screening Of The Indonesian Medicinal Plants Database To Discover Potential Dipeptidyl Peptidase-4 Inhibitors. International Journal of Applied Pharmaceutics, 60. https://doi.org/10.22159/ijap.2020.v12s1.ff008
- Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., Marsilio, F., McCann, M. E., Patel, R. A., Petrov, A., Scapin, G., Patel, S. B., Roy, R. S., Wu, J. K., Wyvratt, M. J., Zhang, B. B., Zhu, L., Thornberry, N. A., & Weber, A. E. (2005). (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Journal of Medicinal Chemistry, 48(1), 141–151. https://doi.org/10.1021/jm0493156
- Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: methods and applications. Nature Reviews Drug Discovery, 3(11), 935–949. https://doi.org/10.1038/nrd1549
- Kristianto, H., Khotimah, H., Sholeha, R. A., Mardianto, E. W., Sani, H. C., & Paratiwi, H. A. (2022). The Effects of Javanese Turmeric (Curcuma xanthorriza Roxb) on Fibroblasts, Granulation, Blood Vessel Density, and Contraction in Wound Healing of STZ-Induced Diabetic Rats. Kuwait Journal of Science. https://doi.org/10.48129/kjs.15261
- Kusuma, I. Y., & Maesaroh, Y. Y. (2020). THE PARE FRUIT ACTIVITY (Momordica charantia L.) AS HERBAL ANTI-HYPERGLYCEMIC FOR DIABETES MELLITUS CONDITIONS: LITERATURE REVIEW. JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X, 12(2), 186. https://doi.org/10.35617/jfionline.v12i2.20
- Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1–3), 3–26. https://doi.org/10.1016/S0169-409X(00)00129-0
- Liu, Y., Grimm, M., Dai, W. T., Hou, M. C., Xiao, Z. X., & Cao, Y. (2020). CB-Dock2: Improved protein–ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Research, 48(W1), W432–W438. https://doi.org/10.1093/nar/gkaa416
- Meduru, H., Wang, Y., Tsai, J. J. P., & Chen, Y. (2016). Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation. International Journal of Molecular Sciences, 17(6), 920. https://doi.org/10.3390/ijms17060920
- Mohd. Javed Naim. (2024). A Review of Dipeptidyl Peptidase-4 (DPP-4) and its potential synthetic derivatives in the management of Diabetes Mellitus. Journal of Angiotherapy, 8(1). https://doi.org/10.25163/angiotherapy.819417
- Nabeno, M., Akahoshi, F., Kishida, H., Miyaguchi, I., Tanaka, Y., Ishii, S., … Matsumoto, Y. (2013). A comparative study of the binding modes of recently launched DPP-4 inhibitors. Biochemical and Biophysical Research Communications, 434(2), 191–196. https://doi.org/10.1016/j.bbrc.2013.03.010
- Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of Medicinal Chemistry, 58(9), 4066–4072. https://doi.org/10.1021/acs.jmedchem.5b00104
- Rahmawati, A., & Hargono, A. (2018). Dominant Factor of Diabetic Neuropathy on Diabetes Mellitus Type 2 Patients. Jurnal Berkala Epidemiologi, 6(1), 60. https://doi.org/10.20473/jbe.v6i12018.60-68
- Saini, K., Sharma, S., & Khan, Y. A. (2023). [Review of DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature]. Frontiers in Molecular Biosciences, 10. Frontiers Media. https://doi.org/10.3389/fmolb.2023.1130625
- Simamora, A., Timotius, K. H., Setiawan, H. S., Yerer, M. B., Ningrum, R. A., & Mun’im, A. (2024). Xanthorrhizol: Its bioactivities and health benefits. Journal of Applied Pharmaceutical Science. https://doi.org/10.7324/japs.2024.159484
- Surya, D. O. (2023). Effectiveness Of Family Empowerment Intervention With Home Care Service Model On Self Management Of Type 2 Diabetes Mellitus Patients. E-Jurnal Medika Udayana, 12(7), 70. https://doi.org/10.24843/mu.2023.v12.i07.p10
- Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/10.1002/jcc.21334
- Wardani, I. K., Aulia, W. N., Saputro, A. H., Ainiya, A., Mariska, S., Kamilaini, D. A., ... & Fransisca, N. P. V. (2025). Bioactive Compounds of Insulin Leaves (Smallanthus sonchifolius) as DPP4 Enzyme Inhibitors in Insulin Signaling Mechanism for the Treatment of Type 2 Diabetes Mellitus: In Silico Study. Chimica et Natura Acta, 13(1), 89-96. https://doi.org/10.24198/cna.v13.n1.55137
- Wulandari, D. D., Salim, H. M., Santoso, A. P. R., & Putri, E. B. P. (2021). Pencegahan Penyakit Diabetes Mellitus melalui Pelatihan Pembuatan Jamu Saintifik bagi Warga Kecamatan Wonokromo Surabaya. Jurnal Surya Masyarakat, 4(1), 104. https://doi.org/10.26714/jsm.4.1.2021.104-111
- Zen, D. A., & Pramiastuti, O. (2019). EFEK HIPOGLIKEMIK KOMBINASI EKSTRAK ETANOL Momordica charantia dan Apium graveolens dengan INDUKSI GLUKOSA. Parapemikir Jurnal Ilmiah Farmasi, 8(1), 5. https://doi.org/10.30591/pjif.v8i1.1292
- Самойлова, Ю. Г., Ваизова, О. Е., Stankova, A. E., Матвеева, М. В., Podchinenova, D. V., Kudlаy, D. А., … Gerasimova, D. A. (2024). [Review of Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review]. Terapevticheskii arkhiv, 96(1), 63. Consilium Medicum. https://doi.org/10.26442/00403660.2024.01.202553
Copyright (c) 2026 Oshada · CC BY-SA 4.0